The Center for Microsurgical Breast Reconstruction Are You a Candidate for Breast Reconstruction?  





Postoperative Morphine Requirements 
 
[ Back To Previous Page ]

Source

Plastic & Reconstructive Surgery

Volume: 107
Number: 2

Feb. 2001

TRAM and DIEP Flaps

Gregory P. Reece, M.D.

In a review of the charts of 158 patients who had undergone breast reconstruction with free transverse rectus abdominis musculocutaneous (TRAM) or deepinferior epigastric perforator (DIEP) flaps and who were treated for postoperative pain with morphine administered by a patient-controlled analgesia pump, the total dose of morphine administered during hospitalization for the flap transfer was measured.

Patients whose treatment was supplemented by other intravenous narcotics were excluded from the study. The mean amount of morphine per kilogram required by patients who had reconstruction with DIEP flaps (0.74 mg/kg, n = 26) was found to be significantly less than the amount required by patients who had reconstruction with TRAM flaps (1.65 fig/kg; n = 132; p < 0.001). DIEP flap patients also remained in the hospital less time (mean, 4.73 days) than did free TRAM flap patients (mean, 5.21 days; p = 0.026), but the difference was less than one full hospital day. It was concluded that the use of the DIEP flap does reduce the patient requirement for postoperative pain medication and therefore presumably reduces postoperative pain. It may also slightly shorten hospital stay. (Plast. Reconstr. Surg. 107: 338, 2001.)

The deep inferior epigastric perforator (DIEP) flap is a relatively new modification of the free transverse rectus abdominis musculocutaneous (TRAM) flap in which branches of the deep inferior epigastric artery and vein are dissected out of the rectus abdominis muscle so that only blood vessels, and no muscle, are harvested with the flap (Figs. 1 and 2) . In this way, donor-site morbidity is minimized and postoperative pain is reduced. Patients recover from the surgery more quickly and seem to require less pain medication.

With patient-controlled analgesia systems, patients control the amount of narcotic pain medication so that they receive just enough medication to control their postoperative pain but no more. To avoid constipation and nausea, patients are motivated to minimize the amount of narcotic used, and to increase their mobility, they generally prefer to have the pump discontinued as soon as they no longer need it. Consequently, the amount of narcotic medication consumed by the patient can be considered a rough indicator of the amount and duration of postoperative pain.

We decided to test the hypothesis that the DIEP flap causes less postoperative pain than the standard free TRAM flap by measuring the amount of narcotic medication used by each patient and comparing the amounts used by patients who had reconstructions with different types of flaps. We also wanted to see whether there was a difference in the length of hospital stay and whether or not any difference was either statistically or clinically significant.

Patients and Methods

All patients who underwent breast reconstruction at The University of Texas M. D. Anderson Cancer Center with free TRAM or DIEP flaps between March 1, 1996, and March 31, 2000, and who were treated for postoperative pain with morphine administered by a patient-controlled pump were eligible for the study. Virtually all patients who undergo breast reconstruction in our institution are treated with narcotics, using a patient-controlled pump. Morphine is usually the narcotic of choice, but some patients do not tolerate morphine well and are therefore given alternative drugs. Patients who had received intravenous drugs other than morphine (such as Dilaudid or meperidine) were excluded from this study, even if they had also received morphine. Flap choice was determined by surgeon preference. Because patient assignment to a surgeon was determined by a scheduling nurse and was usually random, the choice of flap technique in most cases was random as well. Patient charts were selected at random for review, except that all eligible DIEP flaps performed during the study period were included. The study was concluded when enough patients had been accrued to allow valid comparisons between the DIEP and free TRAM flap groups.

The mean dose of morphine (both in mg of morphine and in mg/kg) was calculated for each group and comparisons made using the test with independent samples. A two-way factorial analysis was also performed using flap type and bilateral reconstruction to see whether laterality affected the results. No other correction was made for multiple testing. Differences with p values less than 0.05 were considered to be statistically significant.

Results
During the study period, 158 patients' cases were reviewed. No patients were excluded from the study because a patient-controlled pump was not used, so use of the pump was universal and did not bias our results. Of the reviewed patients, 26 had reconstructions with DIEP flaps and 132 had reconstructions with free TRAM flaps (Table 1) .

Patients who had reconstructions with DIEP flaps used significantly less morphine (mean dose, 50.96 mg) than did patients who had reconstructions with free TRAM flaps (mean dose; 1O7.04 mg; p < 0.001). Patients who had reconstructions with DIEP flaps also used significantly less morphine per kilogram (mean dose, 0.74 mg/kg) than did patients reconstructed with free TRAM flaps (mean dose, 1.65 mg/kg; p < 0.001). Patients who had reconstructions with DIEP flaps also had a mean hospital stay (4.73 days) that was shorter than that of free TRAM flap patients (5.21 days, p = 0.026) .

Patients who had unilateral reconstructions with DIEP flaps (Table II) used significantly less morphine (mean dose, 54.25 mg) than did patients who had unilateral reconstructions with free TRAM flaps (mean dose, 102.89 mg; p < 0.001). They also used significantly less morphine per kilogram (mean dose, 0.79 mg/kg) than did patients who underwent reconstructions with free TRAM flaps (mean dose, 1.59 mg/kg; p = 0.002). In patients who underwent unilateral reconstruction, those who had DIEP flaps also had a mean hospital stay (4.71 days) that was shorter than that of those who had free TRAM flaps (5.10 days), but the difference was not statistically significant (p = 0.077) .

The results in patients who had bilateral reconstructions are listed in Table III. Patients with bilateral DIEP flaps required far less morphine (mean dose, 11.50 mg) than did the patients who underwent reconstructions with free TRAM flaps (mean dose, 120.55 mg), but because the sample of patients who had bilateral reconstructions with DIEP flaps was so small, statistical analysis was not attempted within this group. Morphine use was compared between unilateral and bilateral free TRAM reconstructions, however. In this comparison, women with bilateral reconstructions used more morphine per kilogram (mean, 1.85 mg/kg) than did women with unilateral reconstructions (mean, 1.59 mg/kg), but the difference was not statistically significant (p = 0.246). A two-way factorial analysis of morphine consumption per kilogram showed that flap type was significantly associated with reduced morphine use in this series (p = 0.001) but that unilateral reconstruction was not (p = 0.621) .

Table I
Mean Postoperative Morphine Patient-Controlled Pump Use and Hospitalization after Breast Reconstruction, by Type of Flap Used: All Patients

  Morphine Dose Morphine Dose Hospital Stay
Flap Group No. of Patients Dose in mg SD Dose in mg/kg SD No. of Days SD
DIEP 26 50.96 37.59 0.74 0.53 4.73 0.96
Free TRAM 132 107.04 73.05 1.65 1.03 5.21 0.99



Discussion

In our view, the DIEP flap is a special modification of the free TRAM flap in which no muscle or fascia is killed and transferred with the flap. Although some would argue that the DIEP flap is in fact an entirely different type of flap because it is not musculocutaneous in nature, it uses the same blood supply and skin paddle as the free TRAM flap and is used for the same purposes. Moreover, there is considerable variation in free TRAM flaps between those containing the full width of the rectus abdominis muscle and fascia and those containing only a small piece of muscle. The DIEP flap, for some purposes, can therefore be considered as one end of a continuum that contains all TRAM and DIEP flaps, notwithstanding its special differences.

The DIEP flap has been advocated by many surgeons, especially in Europe, as a way of performing autologous-tissue breast reconstruction with less donor-site morbidity than other types of TRAM flaps. The reduced morbidity is achieved by avoiding sacrifice of any rectus abdominis muscle or fascia. In this way, post- operative pain and abdominal weakness are minimized or avoided. It is likely that relatively low tension on the fascial repair, in particular, contributes significantly to the reduced postoperative pain found in DIEP flap patients. The beneficial effect of not removing fascia is increased by the absence of any need to plicate the opposite side for symmetry.

This study confirms that patients who have had breast reconstruction with DIEP flaps do have significantly less need for postoperative pain medication than do patients who have had standard free TRAM flaps. Differences in pain medication between patients with the DIEP flap and those with the free TRAM flap were highly significant, both statistically and clinically. This confirms our impression that patients who undergo reconstruction with DIEP flaps have less postoperative pain and recover more rapidly from their surgery than do patients with TRAM flaps. The differences were real and were noticed by patients, nurses, and surgeons alike.

Table II
Mean Postoperative Morphine Patient-Controlled Pump Use and Hospitalization after Breast Reconstruction, by Type of Flap Used: Unilateral Reconstructions

  Morphine Dose Morphine Dose Hospital Stay
Flap Group No. of Patients Dose in mg SD Dose in mg/kg SD No. of Days SD
DIEP 24 54.25 37.22 0.79 0.53 4.71 0.95
Free TRAM 101 102.89 72.66 1.59 1.00 5.10 0.89


As expected, patients with bilateral TRAM flap reconstructions needed more morphine than patients who had unilateral TRAM flap reconstructions, but the differences did not reach statistical significance, probably because of the small sample sizes. Interestingly, pain medication use was not increased in patients who had bilateral DIEP flaps, suggesting that the main source of pain in DIEP flap patients may be in places other than the abdominal wall.

Patients who underwent reconstructions with DIEP flaps tended to leave the hospital sooner than patients who underwent reconstructions with standard free TRAM flaps, but the difference was small. For all patients in this series, the difference in hospital stay between the two groups was only 0.48 days. For unilateral reconstructions (a more appropriate group to compare), the difference was only 0.39 days. Although these differences are probably real and might have reached statistical significance in a larger series, the clinical (and financial) impact was relatively minor. Patients with DIEP flaps. were kept in the hospital for at least 4 days for flap monitoring even though they did not need hospitalization for pain control, a fact that may well have minimized the difference in length of hospital stay. 

Table III
Mean Postoperative Morphine Patient-Controlled Pump Use and Hospitalization after Breast Reconstruction, by Type of Flap Used: Bilateral Reconstructions

  Morphine Dose  
Flap Group No. of Patients Dose in mg mg/kg Days In Hospital
DIEP 2 11.50 0.16 5.00
Free TRAM 31 120.55 1.85 5.58


This report supports the efficacy of the DIEP flap in reducing abdominal donor-site morbidity. It should not imply, however, that all other types of TRAM flaps are obsolete or inferior to the DIEP flap. The DIEP flap causes less donor-site morbidity, but it also is supplied by fewer perforators and therefore has less blood supply than the usual free TRAM flap. For some patients, the DIEP flap may well be the method of choice. For others, those who require a more robust flap blood supply, other flaps may be preferred. This subject, however, is beyond the scope of this article and will be covered in a separate report.

In conclusion, our data suggest that the DIEP flap does in fact cause less postoperative pain than other types of TRAM flaps. As such, it has real advantages and deserves serious consideration by surgeons who perform postmastectomy breast reconstruction with autologous tissues.

References

1. Koshima, I., and Soeda, S.  Inferior epigastric artery skin flaps without rectus abdominis muscle. Br. J. Plast. Surg. 42: 645, 1989.

2. Allen, R. J., and Treece, P.  Deep inferior epigastric perforator flap for breast reconstruction. Ann. Plast. Surg. 32: 32, 1994.

3. Blondeel, P. N., and Boeckx, W. D.  Refinements in free flap breast reconstruction: The free bilateral deep inferior epigastric perforator flap anastomosed to the internal mammary artery. Br. J. Plast. Surg. 47: 495, 1994. 

4. Blondeel, P. N.,  One hundred free DIEP flap breast reconstructions: A personal experience. Br. J. Plast. Surg. 52: 104, 1999. 

5. Hamdi, M., Weiler-Mithoff, E. M., and Webster , M. H. C.  Deep inferior epigastric perforator flap in breast reconstruction: Experience with the first 50 flaps. Plast. Reconstr. Surg. 103: 86, 1999. 

6. Feller, A. M., and Galla, T. J.  The deep inferior epigastric artery perforator flap. Clin. Plas. Surg. 25: 197, 1998. 

7. Blondeel, P. N., Van Landuyt, K., and Monstrey, S. J.  Surgical-technical aspects of the free DIEP flap for breast reconstruction. Oper. Techn. Plast. Reconstr. Surg. 6: 27, 1999.

 
Breast Recontstruction I Surgery Preparation I Media I Medical Articles I Get Started I Home  
breast reconstruction, breast sugery, mastectomy, insurance, reconstructive surgery, breast implant, nipple reconstruction, breast augumentation, breast enhancement, new orleans, diep, igap, sgap, gap flap, siea flap, surgery, breat nipple reconstruction, treament options, dr. allen